Confidential Presentation – April 2011PowerpointTemplates
(1) Generic (2) No skills or companies willingness wishing to undertaketo extend their developments portolios (3) Neogen develops and licenses out
API DEVELOPMENTPRODUCT SELECTION / FEASABILITY C 2 orFINISHED DOSE DEVELOPMENT – e Market intel, patent search, formulation, risk assessment, lab 4 co scale batches, manufacturingREGISTRATION FILE COMPILATION ye facilities (capacity), commercial m scale production, stability testing, ar pe release and controlled transport,SUBMISSION / REGISTRATION s warehousing, regulatory strategy. te ncSUPPLY / SUPPORT eSALES AND MARKETING
Development and registration blow fill seal, lyophilized (freeze dried), standard solutions development (usually) performed inhouse production outsourced located in oa. Greece, Germany, France, India and ItalyFirst mover advantage on several productsFirst product launched
Development and registration Creams and Nasal spraysEntry hurdle: requirement for clinical testingPerformed with external development and production partnersin EU
Eric Dubois: 27 years of experience in the pharmaceutical industryincluding general management of ratiopharm Belgium and responsible ofdossier development at Docpharma.Khaled Dandachi: 28 years of experience in technical development oforiginator and generic drugs, including for Docpharma, Pfizer, Federa,Aguettant, Merck-Génériques, Lelin.Thomas Jacobsen: 12 years of experience in the pharmaceuticalindustry, focused on licensing and business development.
Esther Kranenburg: 9 years of experience in the pharmaceuticalindustry, focused on licensing and business development. Responsible forlicensing for Western Europe and Poland. Email: email@example.com / Cell: +31 6 2360 1406Tristram Lake: 9 years of experience in the pharmaceutical industry,focused on licensing and business development. Responsible for licensingfor CEE (excluding Poland), CIS, Greece, Israel, Italy, Portugal, Russia,Spain and Turkey. Email: firstname.lastname@example.org / Phone: +36 1709 2820 / Cell: +36 302 133 497 www.neogen.be